Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces Undetectable Ebola Virus in Patient Treated with Hemopurifier®
Therapy
SAN DIEGO - November 6, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic
devices to address infectious disease and cancer, announced today that
officials at Frankfurt University Hospital have reported undetectable virus in
an ebola patient previously disclosed to have received Hemopurifier® therapy.
In an article entitled: "Ugandan Doctor Cured of Ebola in Germany,"
The Wall Street Journal has reported that hospital officials indicated the
patient is no longer infected with ebola virus and is heading toward a full
recovery.
The
Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets
the rapid elimination of viruses and immunosuppressive proteins from the
circulatory system of infected individuals. At present, no antiviral therapy or
vaccine has proven to be effective against Ebola virus infection in humans.
According to the World Health Organization (WHO), more than 5,000 deaths have
been attributed to the current ebola virus epidemic. The patient at Frankfurt
University Hospital was administered Hemopurifier® therapy through special
approval from The Federal Institute for Drugs and Medical Devices
(Bundesinstitut fur Arzneimittel und Medizinprodukte, BfArM), an independent
federal higher authority within the portfolio of the Federal Ministry of Health
of Germany.
"It is truly wonderful that the
patient, who was reported to be suffering from multiple organ failure, is now
recovering from ebola infection," stated Aethlon founder and CEO, Jim Joyce.
"In the coming days, we will disclose the venue of a public presentation
that will report treatment data including the quantification of viral load
reduction and viruses captured by our Hemopurifier during the treatment of this
patient."
In the care of ebola-infected individuals,
the Hemopurifier targets two unmet medical needs: the rapid elimination of
circulating viruses to inhibit continued progeny virus replication and the
direct targeting of shed glycoproteins that overwhelm the host immune response.
The device can be deployed for use within the global infrastructure of dialysis
and CRRT machines already located in hospitals and clinics.
Aethlon further disclosed that it is
preparing to initiate U.S. clinical studies of Hemopurifier therapy based on
the United States Food and Drug Administration's (FDA) approval of an
Investigational Device Exemption (IDE) that was previously submitted by the
Company. The study will contribute safety data to advance the device as a
broad-spectrum countermeasure against pandemic threats, including ebola and
chronic viral pathogens such as HIV and Hepatitis C (HCV).
To date, Hemopurifier therapy has been
successfully administered in approximately one hundred treatment experiences in
health compromised HIV and HCV infected individuals. These studies were
conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and
the Medanta Medicity Institute, all located in India. In vitro validation
studies that demonstrated the ability of the Hemopurifier to capture Zaire and
other strains of ebola virus were conducted by researchers at the United States
Army Medical Research Institute for Infectious Diseases (USAMRIID) and the
United States Centers for Disease Control and Prevention (CDC).
Read this release
in full at: http://www.investorideas.com/CO/AEMD/news/2014/11061.asp
About Aethlon Medical, Inc.
Aethlon Medical creates targeted
therapeutic devices to address infectious disease, cancer and neurodegenerative
disorders. The company's lead product is the Aethlon Hemopurifier®, a
first-in-class device that selectively targets the rapid elimination of
circulating viruses and tumor-secreted exosomes that promote cancer
progression. Exosome Sciences, Inc. is a majority owned subsidiary that is
advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be
forward-looking and involve risks and uncertainties. Such forward-looking
statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements
of Aethlon Medical, Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without limitation,
that the ESI will not be able to commercialize its future products, that the
FDA will not approve the initiation of the Company's clinical programs or
provide market clearance of the company's products, future human studies
whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the
Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness
to established cancer or hepatitis C therapies or as a standalone cancer or
hepatitis C therapy or as a broad spectrum defense against viral pathogens,
including ebola, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, mining stocks, oil and gas stocks and more...
